

THE RETICULOCYTE IN SICKLE CELL ANEMIA: BIOMARKER TO THERAPEUTIC TARGET

Atul Desai (BAMS, FIIM, PhD)^{1*}, Dr. Kavita Desai (BAMS, PGDHHM)², Jayesh C. Shah (M.Sc (Micro))³ and Dr. Danish Javed⁴

^{1,2}Dhanvantari Clinic Ayurveda Health Care & Research Center, Vyara-394650.

³Suraj Clinical Laboratory, Vyara-394650.

⁴Senior Medical Officer (Ayush), Department of Ayush, All India Institute of Medical Sciences. Bhopal.



*Corresponding Author: Atul Desai (BAMS, FIIM, PhD)

Dhanvantari Clinic Ayurveda Health Care & Research Center, Vyara-394650.

Article Received on 07/07/2025

Article Revised on 27/07/2025

Article Accepted on 17/08/2025

ABSTRACT

Sickle Cell Anemia (SCA) is a hereditary hemoglobinopathy characterized by chronic hemolytic anemia and recurrent vaso-occlusive crises (VOCs). Reticulocytes—immature red blood cells—are increasingly recognized not only as markers of bone marrow activity but also as active contributors to SCA pathophysiology. This study reviews the dual role of reticulocytes in disease progression, emphasizing their adhesive properties mediated by surface molecules such as CD36, CD71, and $\alpha 4\beta 1$ integrin, which facilitate endothelial interactions and vascular occlusion. Elevated absolute reticulocyte counts (ARC), particularly in early infancy, correlate with increased risks of stroke, VOCs, and mortality, offering predictive value for clinical outcomes. Therapeutic strategies, including hydroxyurea, crizanlizumab, L-glutamine, and the herbo-mineral formulation T-AYU-HM Premium, show promise in reducing reticulocyte adhesion and improving patient outcomes. Integrating reticulocyte profiling into clinical practice enables early risk stratification and paves the way for personalized interventions. Targeting reticulocyte adhesion represents a promising avenue for reducing disease burden and enhancing the quality of life in SCA patients.

KEYWORDS: Sickle Cell Anemia; Reticulocytes; Absolute Reticulocyte Count (ARC); Medium Fluorescence Reticulocytes (MFR); Vaso-Occlusive Crisis (VOC); Stroke Risk; Adhesion Molecules; CD36; CD71; $\alpha 4\beta 1$ Integrin; Hydroxyurea; Crizanlizumab; L-Glutamine; T-AYU-HM Premium; Biomarkers; Personalized Medicine.

1. INTRODUCTION

Sickle Cell Anemia (SCA) is a hereditary hemoglobinopathy resulting from a mutation in the β -globin gene, leading to the production of sickle hemoglobin (HbS). The disease is characterized by chronic hemolysis, anemia, and recurrent VOCs. Reticulocytes, traditionally viewed as markers of erythropoietic activity, have gained attention for their active role in SCA pathophysiology. This paper aims to elucidate the evolving understanding of reticulocytes in SCA, highlighting their diagnostic, prognostic, and therapeutic significance.

2. Reticulocytes: More Than a Marker

2.1 Biology and Function

Reticulocytes are immature red blood cells released from the bone marrow in response to anemia. In SCA, chronic hemolysis leads to persistent reticulocytosis. These cells differ from mature erythrocytes in their surface protein expression, including CD36, CD71 (transferrin receptor), and $\alpha 4\beta 1$ integrin, which confer adhesive properties.

2.2 Adhesion and Vaso-Occlusion

The adhesive nature of sickle reticulocytes plays a central role in initiating VOCs. These cells interact with endothelial cells and other blood components, forming aggregates that obstruct microvasculature. This cascade results in ischemia, pain, and organ damage.

3. Reticulocyte Count as a Predictor of Disease Severity

3.1 Early Infancy as a Critical Window

Elevated Absolute Reticulocyte Count (ARC) in infants aged 2–6 months correlates with increased risk of stroke, death, and frequent hospitalizations. This period marks a transition from fetal hemoglobin (HbF) to HbS, and a high ARC reflects a rapid and aggressive switch, indicating severe disease progression.

3.2 Predicting Vaso-Occlusive Crises

In older children and adults, reticulocyte parameters, including medium fluorescence reticulocytes (MFR), can predict VOCs. Studies show that high ARC and MFR

levels are associated with increased VOC incidence in the following year.

3.3 Stroke Risk Assessment

Reticulocyte percentages are linked to cerebrovascular complications. Higher ARC correlates with elevated transcranial Doppler (TCD) velocities, a known stroke risk factor in pediatric SCA patients.




Figure 1: Correlation Between ARC Levels and Disease Severity Indicators.

4. Therapeutic Targeting of Reticulocyte Adhesion

4.1 Hydroxyurea (HU)

Hydroxyurea is a cornerstone of SCA therapy. Beyond increasing HbF levels, HU reduces the expression of adhesion molecules on reticulocytes, diminishing their “stickiness” and preventing VOCs. Clinical improvements often precede HbF elevation, underscoring HU’s anti-adhesive effects.

4.2 Anti-Adhesion Agents

Crizanlizumab, a monoclonal antibody targeting P-selectin, inhibits reticulocyte-endothelium interaction. Clinical trials demonstrate its efficacy in reducing VOC frequency. L-Glutamine reduces oxidative stress and endothelial adhesion of sickle cells, contributing to fewer VOCs and improved patient outcomes.

4.3 T-AYU-HM Premium

T-AYU-HM Premium, a herbo-mineral formulation developed and clinically evaluated, has shown promising results in managing sickle cell anemia (SCA), particularly by addressing complications linked to reticulocyte adhesion and vaso-occlusive crises (VOCs).

5. Personalized Medicine and Future Directions

The integration of reticulocyte profiling into clinical practice enables risk stratification and personalized treatment. Early identification of high-risk infants through ARC can guide timely intervention. Future research should focus on:

- Developing novel anti-adhesion therapies.
- Understanding molecular mechanisms of reticulocyte adhesion.
- Exploring gene therapy and CRISPR-based approaches targeting adhesion pathways.

6. Hemoglobin Role and Comparison

Hemoglobin is a protein in red blood cells responsible for transporting oxygen. In SCA, a mutation causes the production of hemoglobin S (HbS), which polymerizes under low oxygen, distorting red cells into a sickle shape. These cells are prone to rupture and vaso-occlusion, leading to anemia and complications.




Figure 2: Comparison of Hemoglobin Levels: Normal vs. Sickle Cell Anemia.

7. Reticulocyte Biomarkers and Their Clinical Significance

Biomarker	Clinical Significance
CD36	Promotes adhesion to endothelial cells, contributing to vaso-occlusion
CD71 (Transferrin Receptor)	Indicates immature reticulocytes; involved in iron uptake
$\alpha 4\beta 1$ Integrin	Facilitates cell adhesion, increasing risk of vascular blockage
Absolute Reticulocyte Count (ARC)	Predicts disease severity, stroke risk, and VOC frequency
Medium Fluorescence Reticulocytes (MFR)	Associated with future VOCs; used in risk stratification

8. CONCLUSION

Reticulocytes in SCA are not passive bystanders but active instigators of disease pathology. Their adhesive properties contribute to VOCs and stroke risk, making them valuable biomarkers and therapeutic targets. Advances in understanding reticulocyte biology have paved the way for personalized medicine in SCA, promising improved outcomes through early intervention and targeted therapy.

9. REFERENCES

- Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. *Blood.*, 2013; 122(24): 3892–3898. doi:10.1182/blood-2013-05-498311. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC7125006/>
- Telen MJ, Malik P, Vercellotti GM. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. *Nat Rev Drug Discov.*, 2019; 18(2): 139–158. doi:10.1038/s41573-018-0003-2. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC4845996/>
- Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. *N Engl J Med.*, 2017; 376(5): 429–439. doi:10.1056/NEJMoa1611770. Available from: <https://pubmed.ncbi.nlm.nih.gov/31735458/>
- Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of the efficacy and safety of hydroxyurea in children with sickle cell anemia. *Br J Haematol.*, 2016; 174(2): 276–285. doi:10.1111/bjh.14055. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S0268960X19301511>
- Nur E, Biemond BJ, Otten HM, et al. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. *Am J Hematol.*, 2011; 86(6): 484–489. doi:10.1002/ajh.22045. Available from: <https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0153244>
- Hoppe C, Klitz W, D'Harlingue A, et al. Confirmation of an association between the TGF β /BMP pathway and stroke in sickle cell anemia. *Am J Hematol.*, 2012; 87(9): 870–872. doi:10.1002/ajh.23272. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6328043/>
- Nouriae M, Reading NS, Campbell A, et al. Association of G6PD deficiency with lower hemolysis and higher hemoglobin F in sickle cell disease. *PLoS One.*, 2013; 8(7): e70794. doi:10.1371/journal.pone.0070794. Available from: <https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0070794>
- Minniti CP, Eckman J, Sebastiani P, et al. Leg ulcers in sickle cell disease. *Am J Hematol.*, 2010; 85(10): 831–833. doi:10.1002/ajh.21826. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9044919/>
- Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. *N Engl J Med.*, 1995; 332(20): 1317–1322. doi:10.1056/NEJM199505183322001. Available from: <https://www.sciencedirect.com/science/article/pii/S021925820483656>

10. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. *J Clin Invest.*, 2017; 127(3): 750–760. doi:10.1172/JCI89741. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6645400/>
11. Desai A, et al. Randomized, multicentric parallel-group clinical trial of the herbo-mineral formulation T-AYU-HM Premium in sickle cell anemia patients. *J Young Pharm.*, 2025; 17(2).